ev3 to Acquire Chestnut Medical Technologies
Posted on June 2, 2009
Filed Under Neurovascular | Leave a Comment
ev3 signed a definitive agreement to acquire Chestnut Medical Technologies, the developer of the Pipeline Embolization Device for cerebral aneurysm repair. The transaction will add unique, paradigm shifting technology to ev3 neurovascular franchise.
Uptake Raises $3 Million Bridge Financing
Posted on December 12, 2008
Filed Under Respiratory | Leave a Comment
Uptake Medical, a Seattle-based medical device company developing minimally invasive therapies for emphysema and COPD, has raised $3 million in bridge financing. Uptake’s lead product is a bronchoscopic catheter for delivering vapor to emphysematous lung regions.
According to the company, applying energy to emphysematous lung regions scars down those regions allowing better functioning lung regions to expand thus offering patients improved overall breathing mechanics. Uptakes dubs its technology Bronchoscopic Thermal Vapor Ablation or (BTVA) for short.
Novasys Secures $50 Million in Series D Financing
Posted on May 15, 2008
Filed Under Women Health | Leave a Comment
Novasys Medical, the developer of Renessa, a non-surgical treatment for female stress urinary incontinence (SUI), secured $45 million in Series D preferred stock financing.
The round was led by Versant Ventures, with ThreeArch Partners and Skyline Ventures also participating as new investors.
Money will be used to further development and commercialization efforts of Renessa.
Veran Medical Secures $5 Million to Launch Cancer Device
Posted on May 12, 2008
Filed Under Interventional Oncology | Leave a Comment
Veran Medical Technologies, a privately held image-guided medical device company, secured $5 million in venture capital and private financing to drive adoption of its IG4 delivery system for minimally invasive biopsy and ablation of cancer. St. Louis-based Prolog Ventures led the round and was joined by Advantage Capital Partners and existing private investors.
CyDen Raises Funds to Expand Marketing of iPulse
Posted on May 12, 2008
Filed Under Cosmetic Interventions | Leave a Comment
CyDen, a pioneer of intense pulsed light (IPL) technology, received a $5 million capital injection from Unilever Ventures in a new round of investment managed by Longbow Capital.
CyDen’s iPulse range of products miniaturizes and simplifies light-based treatments for permanent hair reduction, acne, skin blemishes, pigmentation as well as phototherapy for anti-aging and wrinkle reduction.
The small and portable IPL devices deliver safe and effective results at lower energy levels providing Spa business owners a reliable and cost-effective entry into the lucrative aesthetic and beauty market.